Amgen's master trial for Hard-to-Treat prostate cancer hits early hurdles

NCT ID NCT04631601

Terminated Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This master trial tested several drug combinations, including a new targeted therapy called acapatamab, in 65 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to check safety and early signs of effectiveness. The study was terminated early, so results are limited, but it may provide clues for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acapatamab (PSMA-targeted therapy), enzalutamide, abiraterone, and AMG 404 (PD-1 inhibitor)
What this could lead to: If successful, this could point toward new treatment options for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This early-phase trial was terminated, so results are limited. The drugs may cause significant side effects, and it is unclear if they will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Akademiska sjukhuset

Uppsala, 75185, Sweden
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Karolinska Universitetssjukhuset Solna

Stockholm, 171 76, Sweden
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
Rigshospitalet

København Ø, 2100, Denmark
Royal Marsden Hospital

Sutton, SM2 5PT, United Kingdom
Skanes universitetssjukhus

Lund, 221 85, Sweden
St Vincents Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of California San Francisco Mission Bay Campus

San Francisco, California, 94158, United States
University of California at Irvine Medical Center

Orange, California, 92868, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.